---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-029456"
form_type: "8-K"
ticker: "ARWR"
cik: "0000879407"
company_name: "ARROWHEAD PHARMACEUTICALS, INC."
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-22T00:25:00.124139+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Arrowhead sells olpasiran royalty rights to Royalty Pharma for up to $410M

## Summary
- Royalty Pharma pays $250M upfront for future royalties from Amgen on olpasiran.
- Up to $160M in milestones: $50M on Phase 3 enrollment, $50M on FDA approval, $60M after annual royalty receipt threshold.
- Arrowhead retains eligibility for all milestone payments from Amgen under the original license agreement.
- Transaction provides non-dilutive cash to fund Arrowhead's pipeline and operations.

## SEC filing metadata
- accession: 0001628280-22-029456
- form_type: 8-K
- ticker: ARWR
- cik: 0000879407
- company_name: ARROWHEAD PHARMACEUTICALS, INC.
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/879407/000162828022029456/0001628280-22-029456-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/879407/000162828022029456/arwr-20221109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-029456
- JSON: https://secwatch.observer/filing/0001628280-22-029456.json
- Plain text: https://secwatch.observer/filing/0001628280-22-029456.txt

## Key facts
- Material Agreements
  ARROWHEAD PHARMACEUTICALS, INC. entered into Royalty Purchase Agreement with Royalty Pharma Investments 2019 ICAV valued at up to $410 million (effective 2022-11-09).
  - Action: entry
  - Counterparty: Royalty Pharma Investments 2019 ICAV
  - Value: up to $410 million
  - Effective: 2022-11-09
  source text: Arrowhead Pharmaceuticals, Inc. (the “Company”) entered into a Royalty Purchase Agreement (the “Purchase Agreement”) with Royalty Pharma Investments 2019 ICAV (“Royalty Pharma”), pursuant to which Royalty Pharma agreed to pay up to $410 million in cash to the Company
  evidence_url: https://www.sec.gov/Archives/edgar/data/879407/000162828022029456/0001628280-22-029456-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.